Entera Bio Shares Surge 66% On Positive Results From Osteoporosis Treatment Study

Shares of Entera Bio Ltd. (ENTX) are surging over 66% on Wednesday morning after the biotech company's mid-stage trial of osteoporosis treatment met primary and secondary points.

ENTX is currently trading at $7.48, up $2.99 or 66.59%, on the Nasdaq. The stock has traded between $1.00 and $10.16 in the 52-week period.

Entera announced the final 6-month bone mineral density (BMD) results from the completed Phase 2 clinical trial of EB613 for the treatment of osteoporosis. EB613 is an oral formulation of human parathyroid hormone or PTH, positioned to be the first oral bone building product to treat osteoporosis patients.

Subjects receiving the 2.5 mg dose of EB613 showed significant dose-related increases in BMD at the lumbar spine, total hip, and femoral neck at 6 months. The study's primary efficacy endpoint, a statistically significant increase in P1NP at 3 months was achieved, as previously reported.

The company said EB613 is positioned to be the first oral bone building agent for the treatment of osteoporosis.

For comments and feedback contact: editorial@rttnews.com

Business News

Get Access to Premium Stock Alerts with RTT Biotech Investor.
Follow RTT